

# [24412] Metastasis genes relate to colon cancer

*By* Haotang Wei

1

2 **Comprehensive analysis of metastasis-related genes reveals a gene signature predicting the**  
3 **survival of colon cancer**

4 **Running title: Metastasis genes related to colon cancer**

5

6 Hao-tang Wei<sup>1#</sup>, Ji-lin Li<sup>2#</sup>, Ming-zhi Xie<sup>2</sup>, Rong-e Lei<sup>3</sup>, Bang-li Hu<sup>2</sup>

7

8 <sup>11</sup> 1 Department of Gastrointestinal Surgery, the Third Affiliated Hospital of Guangxi Medical  
9 University, Nanning 530031, China

10 2 Department of Research, Affiliated Tumor Hospital of Guangxi Medical University, Nanning  
11 530021, China.

12 3 Department of Gastroenterology, the First Affiliated Hospital of Guangxi Medical University,  
13 Nanning 530021, China

14

15 <sup>7</sup> #These authors contributed equally to this work.

16

17 Corresponding author: Bang-li Hu

18 Department of Research,  
19 <sup>25</sup> Affiliated Tumor Hospital of Guangxi Medical University,

20 71 Hedi Road, Nanning 530021, China

21 Tel: +86-0771- 5321865; Fax +86-0771- 5321865

22 E-mail: [gxhubl@163.com](mailto:gxhubl@163.com)

23

24

25

## 26 Abstract

27 **Objective** The mechanism underlying colon cancer metastasis remain unclear. <sup>72</sup> This study aimed  
28 to elucidate the genes that are altered during the metastasis of colon cancer and identify genes  
29 that are crucial to the metastasis and survival of colon cancer patients. **Methods** The dataset of  
30 primary and metastasis tissue of colon cancer, and dataset of high and low metastasis capability  
31 of colon cancer cells were selected as training cohort, and the overlapped <sup>7</sup> differentially expressed  
32 genes (DEGs) were screened from the training cohort. The functional enrichment analysis for the  
33 overlapped DEGs was performed. The prognostic value of overlapped DEGs were analyzed in  
34 TCGA dataset, and a gene signature was developed using genes that related to the overall  
35 survival (OS). The <sup>47</sup> prognostic value of the gene signature was further confirmed in a validation  
36 cohort. **Results** 184 overlapped DEGs were screened from the training cohort. Functional  
37 enrichment analysis revealed <sup>63</sup> the significant gene functions and pathways of the overlapped  
38 DEGs. Four hub genes (OXCT1, ACTN4, IL-8, ITGA3) were identified using protein-protein  
39 network analysis. Six genes (ALDH2, NEDD9, FLNA, LBR, TWF1, SRSF1) were closely  
40 related to the OS of colon cancer patients. <sup>71</sup> A gene signature was developed using these six genes  
41 based on their risk score, and the validation cohort indicated that <sup>14</sup> the prognostic value of this  
42 gene signature was high in colon cancer patients. **Conclusions** Our study has demonstrate a gene  
43 profiles <sup>70</sup> involved in the metastasis of colon cancer, and identify a six-gene signature that acts as  
44 an independent biomarker on the prognosis of colon cancer.

45

46

47

48

49

50 <sup>14</sup>  
**Introduction**

51 Colorectal cancer (CRC) is one of the leading malignant cancers in the world, and the colon  
52 cancer accounts for a large part of CRC (Siegel et al. 2017a; Siegel et al. 2017b). During the last  
53 three decades, with the development of new therapies, such as <sup>62</sup>antiepidermal growth factor  
54 receptor antibody therapy and bevacizumab (Castro et al. 2013; Knijn et al. 2010), great  
55 improvement in survival has been for colon cancer patients with localized- and regional disease.  
56 However, metastasis remains the <sup>41</sup>main event that leads to death of a cancer patient. Compared  
57 with the early stage of colon cancer, <sup>1</sup>the prognosis of patients with distant metastasis remained  
58 <sup>1</sup>poor (Siegel et al. 2017b). Progressive accumulation of genetic mutations is recognized as an  
59 important factor results in the development and progression of colon cancer (Sameer 2013).  
60 Hence, exploring the mechanisms of cancer metastasis and searching suitable predictors are  
61 <sup>61</sup>crucial to the diagnosis and treatment of colon cancer.

62 Previously, the TNM stage and pathological characteristics of colon cancer are commonly  
63 used to predict the prognosis and facilitate treatment for colon cancer patients. But there are  
64 some limitations of these methods (Marzouk & Schofield 2011). Recently, several novel  
65 biomarkers have been tested with the aim to improve the prediction of therapeutic response and  
66 <sup>46</sup>prognosis of colon cancer patients (Demirkol et al. 2017; Hu et al. 2014; Xu et al. 2017), which  
67 <sup>15</sup>provide a lot of help in the diagnosis and treatment of colon cancer, but the results were  
68 inconsistent and need to further study.

69 <sup>13</sup>Thus far, metastasis is a major factor for the low survival <sup>45</sup>rate of colon cancer, and the liver

is the most common site of colon cancer metastasis, but the molecular mechanism underlying distant metastasis remains unclear. Therefore, a comprehensive analysis for the molecular alteration and identify prognostic factors is pivotal for the management of metastasis colon cancer patients. In this study, by using the colon cancer data from gene expression omnibus (GEO) and The Cancer Genome Atlas (TCGA), we analyzed the data of colon cancer in primary tumor samples and liver metastasis samples to unveil the potential bridging genes that key to the development colon cancer metastasis and the potential prognostic indicators.

## Materials and methods

### Patient datasets

The colon cancer tissue and cells microarray data (GSE40367(Roessler et al. 2015) and GSE2509 (Provenzani et al. 2006)) was retrieval and download from the GEO (<http://www.ncbi.nlm.nih.gov/geo/>) database in the National Center for Biotechnology Information (NCBI) as the training cohort. The GSE40367 dataset includes seven colon adenocarcinoma (COAD) with liver metastasis species and eight COAD primary tumor species. The GSE2905 dataset includes two colon cancer cell lines (SW480: low metastasis capability and SW620: high metastasis capability). The prognostic value of genes was analyzed using the data of COAD from TCGA. To validate the results from training cohort, we used the GSE41258(Sheffer et al. 2009) dataset that includes 390 species as validation cohort. Since the data were provided by GEO and TCGA database, additional approval by an ethics committee was not needed.

### Identification of overlapped DEGs

93 Statistical software R (version 3.4.2) and packages of Bioconductor<sup>1</sup> were applied to screen  
94 differentially expressed genes (DEGs) between primary tumor tissue and liver metastasis tissue  
95 in GSE40367, the DEGs between SW480 and SW620 in GSE2905 were also screened. Genes  
96 that fulfill the criteria of  $p \text{ value} < 0.05$  and  $|\log FC| \geq 1$ <sup>40</sup> were defined as the DEGs. Then the  
97 intersected DEGs of GSE40367 and GSE2905 were defined as overlapped DEGs. Before  
98 screening of DEGs, the probe level data<sup>18</sup> was converted into gene expression values. If one gene<sup>18</sup>  
99 is corresponding to multiple probe sets, the average data were used as gene expression  
100 values<sup>69</sup>(Qin et al. 2012). We also eliminated genes with over 20% missing values as previous  
101 study did(Liew et al. 2011). After pre-processing the data, t-test methods were used to screen the  
102 DEGs using limma package.

103

#### 104 Functional enrichment analysis of overlapped DEGs

105 Gene Ontology (GO)<sup>30</sup> includes three categories, namely, Biological Process (BP), Molecular  
106 Function (MF), and Cellular Component (CC). To investigate the functional level of DEGs,  
107 DEGs were underwent GO analysis by using DAVID (<https://david.ncifcrf.gov/>). The significant<sup>60</sup>  
108 GO categories was defined with the  $p < 0.05$ . Then the KEGG pathway analysis was conducted<sup>16</sup>  
109 to identify the significant pathways that genes enrichment using DAVID online tool. We defined<sup>16</sup>  
110 the significant pathways with  $p < 0.05$ .

111

#### 112 Integration of PPI network and subnetwork analysis

113 Protein-protein interaction (PPI)<sup>4</sup> network can identity key genes and important gene  
114 modules which are involved in cancer development from interaction level. PPI information of  
115 DEGs was acquired from Search Tool for the Retrieval of Interacting Genes (STRING) database



116 (<http://www.string-db.org/>). Then, Cytoscape software was used for the establishment of PPI  
117 network for all the overlapped DEGs. After the establishment PPI network, the module analysis  
118 was carried out by Molecular Complex Detection (MCODE), a plug-ins of Cytoscape, to detect  
119 the gene modules of the PPI network, and the hub genes of each module was identified by the  
120 score of each gene in the module.

121

## 122 Acquisition of a gene signature from the training cohort

123 The association of overlapped DEGs with the overall survival (OS) of colon cancer patients  
124 was analyzed in COAD dataset from TCGA database using Cox regression analysis in survival  
125 package of R. The gene with p value <0.05 was considered to be independent prognostic factor.  
126 To evaluate the relative contribution of multiple genes for survival prediction when considering  
127 interrelationship among them, we selected the genes with p value <0.05 to develop a prognostic  
128 model by the risk scoring method as previously described. In brief, a prognosis risk score for  
129 predicting OS of colon cancer was established on the basis of a linear combination of the  
130 expression level multiplied by the regression coefficient derived from the multivariate cox  
131 regression model ( $\beta$ ) with the following formula as previously reported: Risk score = expression  
132 of Gene<sub>1</sub> ×  $\beta_1$ Gene<sub>1</sub> + expression of Gene<sub>2</sub> ×  $\beta_2$ Gene<sub>2</sub> + ... expression of Gene<sub>n</sub> ×  $\beta_n$ Gene<sub>n</sub> (Bao et  
133 al. 2014). Using the median risk score as the cutoff, patients were divided into high risk group  
134 and low risk group. Kaplan-Meier curves were used to estimate the survival for patients with  
135 high risk group or low risk group. p <0.05 was defined as significantly different. The time-  
136 dependent receiver operating characteristic (ROC) curve analysis for the gene signature was  
137 preformed using the R package “survivalROC” (Heagerty et al. 2000). All statistical analyses  
138 were performed using R software and Bioconductor.

139

## 140 **Results**

### 141 *Overlapped genes of CRC cells and tissues*

142 The DEGs of GES2905 and GSE40367 were screened based on the selection criteria after  
143 preprocessing raw data. 341 DEGs between colon cancer cells lines SW420 and SW680 cells  
144 were identified in GES2905 dataset, and 7339 DEGs between primary and metastasis tumor  
145 specimens were identified in GSE40367 dataset. By overlapped the DEGs from the two datasets,  
146 we obtained 184 overlapped genes that differentially expressed in both CRC cells and tissues.  
147 The result was displayed in Fig. 1.

148

### 149 *GO and KEGG enrichment analysis*

150 The functions of the 184 overlapped DEGs were then analyzed by GO and KEGG  
151 enrichment analysis. Using the DAVID online tools, we found that the most enriched GO terms  
152 of DEGs that related to BP was Signal transduction, and the MF was Protein binding, and the CC  
153 was Cytoplasm. The KEGG pathway analysis based on the GO results revealed that Thyroid  
154 hormone synthesis was the most significant pathway of the overlapped DEGs. The results were  
155 shown in Fig. 2.

156

### 157 *PPI network and Module screening analysis*

158 Using the data from STRING database, a PPI network for the 184 DEGs consisting of 133  
159 nodes and 138 edges was constructed by Cytoscape software. The overall PPI network was  
160 shown in Fig. 3A. Then the plug-ins MCODE was used to detect the modules in the network, and  
161 four modules were identified, with the OXCT1 (score: 4), ACTN4 (score: 3), IL-8 (score: 3),



162 ITGA3 (score: 3) as the hub genes of each module. The top three modules were shown in Fig. 3B-  
163 D.

164

#### 165 *Prognostic value of overlapped DEGs*

166 The prognostic value of 184 overlapped DEGs was analyzed using the COAD dataset of  
167 TCGA by the multiple Cox regression analysis after adjusted the data of age, gender and TNM  
168 stage, the results showed that only ALDH2, NEDD9, FLNA, LBR, TWF1, SRSF1 were  
169 independent genes that <sup>1</sup>associated with the OS of colon cancer patients, with the beta value as -  
170 1.343, -0.051, 0.492, -0.020, -0.181 and -1.938, respectively. We developed a <sup>59</sup>six-gene signature  
171 by calculating <sup>26</sup>the risk score of each gene, and divided the patients into high risk group and low  
172 risk group based on the median of risk score (Fig. 4A), the survival status and genes expression  
173 level in shown in Fig. 4B-C. The survival analysis revealed that this six-gene signature with high  
174 risk group predicted poor OS of colon cancer patients compared with low risk group, as the p  
175 value <0.001 (Fig. 5A). Using survival ROC analysis, we found <sup>2</sup>that the risk score of this six-  
176 gene signature <sup>2</sup>could largely predict the 1-, 3-, 5-year OS of colon cancer patients, as the value of <sup>14</sup>  
177 area under ROC curve (AUC) was 0.686, 634, 618, respectively (Fig. 5B).

178

#### 179 <sup>39</sup>*Validation cohort confirm the prognostic value of the six-gene signature*

180 The prognostic value of the six-gene signature for the OS of colon patients was further  
181 determined in the validation cohort (GSE41258 datasets, 390 colon patients, mean follow-up  
182 <sup>3</sup>65.3 months). By using the same risk score model and cutoff value deriving from the training  
183 cohort, 390 patients of the validation cohort were classified into either high-risk group (n=195)  
184 or low-risk group (n=195). In consistence with results of the training cohort, the Kaplan-Meier

44  
analysis of this six-gene signature indicated a significant difference between high risk group and low risk group with regard to the OS of colon cancer patients (p=0.005, log-rank test)

187

## 188 Discussion

1 Metastasis is the most lethal characteristic of CRC, accounting for 90% of the mortalities of patients with colon cancer (Li et al. 2017). The 5-year survival rates of colon cancer patients with localized- and regional -disease are up to 91.1% and 71.7%, respectively, but the 5-year survival rates of patients with distant metastasis drop to 13.3% (Siegel et al. 2017a). In addition, the metastatic dissemination of primary tumors is a pivotal cause for the failure of treatment (Deliu et al. 2014; Stein & Schlag 2007). At a molecular level, the distinct metastasis colon cancer is a heterogeneous group of diseases with molecularly and clinically distinct from the primary site of origin (Zarour et al. 2017). Thus, analyzing the molecular alteration of colon cancer with distinct metastasis is benefit for the identification of candidate targets for early diagnosis and treatment of advanced stage of colon cancer patients.

2 To date, some biomarkers has been identified to be the candidate targets for early diagnosis and treatment of colon cancer and rectum cancer, including genes, miRNA, lncRNA and the related signatures. The search for molecular signatures present in a primary tumor that can identify the metastasis potential of each tumor has been described with promising results. Vellinga et al (Vellinga et al. 2017) designed a lymphangiogenic gene set and applied it to large datasets of CRC, and found that this lymphangiogenic gene set was correlated with worse prognosis and consensus molecular subtype-4 in both primary and liver metastatic CRC. Rokavec et al (Rokavec et al. 2017) reported a single gene, RBM47, was down-regulation during CRC progression may promote epithelial-mesenchymal transition and metastasis. Further,

208 proteomic studies of exosomes from cancer cell lines have identified four candidates genes  
209 (MET, S100A8, S100A9, TNC) involved in CRC metastasis (Ji et al. 2013). Other biomarkers,  
210 such as a four -miRNA signature (let-7i, miR-10b, miR-221 and miR-320a) (Hur et al. 2015),  
211 and a six- lncRNA signature were reported to be promising biomarkers for the metastasis and  
212 prognosis of CRC (Hu et al. 2014).

213 In this study, we identified 4 hub genes from the subnetwork of the PPI network, that is  
214 OXCT1, ACTN4, IL-8 and ITGA3. OXCT1 is a key enzyme in ketone body metabolism that  
215 catalyzes the first and rate-determining step of ketolysis. The product of OXCT1 converts to  
216 acetyl-CoA and finally fed into the tricarboxylic acid cycle for oxidation and ATP  
217 production (Zhang & Xie 2017). The role of OXCT1 has been defined in several cancers,  
218 included colorectal cancer, and the OXCT1 expressed at higher levels in the metastatic CRC cell  
219 line CC-M3 (Lee et al. 2016). ACTN4 is a non-muscle-type alpha-actinin, it play an important  
220 role in regulating cytoskeleton organization and involving transcriptional regulation of gene  
221 expression. ACTN4 encodes a nonmuscle, alpha actinin isoform which is concentrated in the  
222 cytoplasm, and involves in metastatic processes, and was reported to enhance cancer cell motility,  
223 invasion, and metastasis. In CRC, ACTN4 was reported to promote CRC cell line invasion by  
224 suppressing focal adhesion maturation (Fukumoto et al. 2015). ITGA3, a member of the integrin  
225 family, joins a beta 1 subunit to form an intact integrin and interacts with extracellular matrix  
226 proteins, including members of the laminin family (Nagata et al. 2013). ITGA3 levels represent  
227 biological traits associated with lymphatic dissemination and local invasiveness. One study  
228 showed that ITGA3 was over-expressed in stages III versus I of CRC patients, and related to the  
229 OS and disease-free survival (Linhares et al. 2015). IL-8 is a pro-inflammatory chemokine  
230 produced by various cell types to recruit leukocytes to sites of infection or tissue injury.

5  
231 Emerging research now indicates that paracrine signaling by tumor-derived IL-8 promotes the  
232 trafficking of neutrophils and myeloid-derived suppressor cells into the tumor microenvironment,  
233 which have the ability to dampen anti-tumor immune responses (David et al. 2016). Lambrechts  
234 et al (Lambrechts et al. 2015) observed that IL-8 plasma levels at baseline and subsequent  
235 increases in IL-8 were associated with worse progression-free survival of metastatic CRC  
236 patients. These studies confirmed our results that the hub genes of the PPI network were crucial  
237 to the metastasis of colon cancer, but further studies remains warrant to determine the underlying  
238 mechanism.

239 Similar to the previous studies, in this study, a signature constructed by six genes was  
240 showed to be good predictor for the OS of colon cancer, among these six genes, the role of  
241 ALDH2, NEDD9, SRSF1 and FLNA were reported to be associated with the CRC in several  
242 studies. ALDH2 is essential for the metabolism and detoxification of a wide range of  
243 endogenous and exogenous aldehyde substrates. it is the rate-limiting enzyme in the ethanol  
244 metabolism, oxidizing acetaldehyde to acetic acid both in the liver and other tissues (Chen et al.  
245 2016). As a novel biological marker, ALDH2 displays an attractive prospect in the screening,  
246 diagnosis and evaluation of the prognosis of many diseases, and the genetic polymorphism of  
247 ALDH2 was significantly correlated with the susceptibility to CRC (Li et al. 2016). NEDD9 is a  
248 non-catalytic scaffolding protein, assembles complexes involving oncogenic kinases, and  
249 regulates the magnitude and duration of cell signaling cascades that controls multiple processes,  
250 which are crucial for tumorigenesis and metastases(Shagisultanova et al. 2015). Study has  
251 showed that downregulation of NEDD9 by apigenin can suppresses migration, invasion, and  
252 metastasis of CRC cells (Dai et al. 2016). With regard to the SRSF1, there was a study reported  
253 that phosphorylation of SRSF1 regulated alternative splicing of tumor-related Rac1b in CRC



254 cells(Goncalves et al. 2014). SRSF1 is a prototypical splicing factor mostly recruited to SREs  
255 classified as exonic splicing enhancers. SRSF1 recognizes degenerate purine-rich sequence  
256 motifs and its binding promotes recognition of both constitutive and alternative exons during  
257 spliceosomal assembly (Sanford et al. 2009). FLNA is an actin-binding protein expressed  
258 ubiquitously within the body with multiple roles both in cell signaling and maintenance of cell  
259 shape and motility. A well-known association already exists between this mutation and disorders  
260 of neuronal migration, vascular function, connective tissue integrity, and skeletal  
261 development(Shelmerdine et al. 2017); FLNA showed low expression in CRC, and was high  
262 correlated with the incidence and development of CRC (Tian et al. 2015). LBR a transmembrane  
263 protein of the inner nuclear membrane. LBR interacts through its nucleoplasmic amino-terminal  
264 domain with both heterochromatin and B-type lamins, and is phosphorylated throughout the cell  
265 cycle, but on different sites in interphase and mitosis (Duband-Goulet et al. 1998). TWF1 is a  
266 conserved actin-binding protein with two actin depolymerizing factor homology domains16 and  
267 belongs to the ADF-H family. It regulates diverse morphological and motile processes by both  
268 sequestering ADP-actin monomers and capping filament barbed ends(Paavilainen et al. 2007).  
269 However, no study has yet reported the role of LBR and TWF1 in CRC, so their role need be  
270 further studied in colon cancers.

271 Compared with previous studies, this study screened the metastasis related genes by  
272 overlapping the DEGs from cancer tissues and cell lines. These tissues included primary colon  
273 cancer tissues and liver metastasis tissues, and the cell lines included primary (SW480) and  
274 metastatic (SW620) human isogenic colorectal cancer cell lines, thus, the overlapped DEGs  
275 could be more reliable in reflecting the genes alteration of metastatic colon cancer. We also  
276 performed a comprehensive analysis for these overlapped DEGs, using GO and KEGG analysis,

277 and identified the function of the genes and the pathways they involved, then the PPI network  
278 and subnetwork analysis revealed the gene-gene interaction and identified four hub genes that  
279 crucial to the network, which provided an insight into the mechanism of colon cancer metastasis.  
280 Furthermore, we analyzed the prognostic value of the overlapped DEGs, and identified six genes  
281 that related to the OS of colon cancer patients. We finally developed a six-gene signature to test  
282 its prognostic value and validated by an independent dataset. Therefore, these results were more  
283 informative and provided a reliable prognostic factors pinpointing a subset of patients with poor  
284 prognosis.

285 However, some limitations need to be noted in this study. First, although metastasis-related  
286 genes of colon cancer were identified and the prognostic value of them were validated in our  
287 study, the results were calculated from microarray or RNA-sequencing technique datasets, thus,  
288 lack of functional validation of the target genes is one of the major limitations of this study.  
289 Therefore, a thorough functional experiments for these genes and corresponding downstream  
290 events to reveal novel diagnostic and therapeutic targets for colon cancer is necessary. Second,  
291 the development of colon cancer metastasis can be caused by many factors, such as KRAS,  
292 BRAF mutation, microsatellite instability, which has been proven to be closely related to the  
293 colon cancer, but due to the limited of datasets, we did not perform stratified analysis based on  
294 these factors, future studies should conduct this analysis to explore the difference under different  
295 conditions. Third, the mean time of follow-up in validation cohort was 65.3 months, thus, a study  
296 including a longer follow-up time is warranted to validate our results in the future.

297 In conclusion, this study has screened a gene profile involving in the metastasis of colon  
298 cancer, and identify four hub genes from the gene profile. We also identify and validate a six-  
299 gene signature that can be served as an indicator of prognosis of colon cancer. Some genes that



300 are not yet <sup>33</sup> proved to be associated with colon cancer metastasis may represent new therapeutic  
301 targets.

302

### 303 Abbreviation:

304 CRC: colorectal cancer; <sup>1</sup> DEGs: differentially expressed genes; GO: Gene Ontology; KEGG:  
305 <sup>54</sup> Kyoto Encyclopedia of Genes and Genomes; OS: overall survival; ROC: receiver operating  
306 characteristic curve; OXCT1: 3-oxoacid CoA-transferase 1; ACTN4: actinin alpha 4; IL-8:  
307 interleukin 8; ITGA3: integrin subunit alpha 3; ALDH2: aldehyde dehydrogenase <sup>42</sup> 2; NEDD9:  
308 neural precursor cell expressed, developmentally down-regulated 9; FLNA: filamin A; LBR:  
309 lamin B receptor; TWF1: twinfilin actin binding <sup>48</sup> protein 1; SRSF1: serine and arginine rich  
310 splicing factor 1; TNC: tenascin C; RBM47: RNA binding motif protein 47; MET: MET proto-  
311 oncogene, receptor tyrosine kinase

312

### 313 Reference

314 Bao ZS, Li MY, Wang JY, Zhang CB, Wang HJ, Yan W, Liu YW, Zhang W, Chen L, and Jiang  
315 T. 2014. Prognostic value of a nine-gene signature in glioma patients based on mRNA  
316 expression profiling. *CNS Neurosci Ther* 20:112-118. 10.1111/cns.12171

317 Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N,  
318 Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis S,  
319 Frost D, Peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer C,  
320 Douglas F, Porteous ME, Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, Kennedy  
321 MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z, and Eeles R.  
322 2013. Germline BRCA mutations are associated with higher risk of nodal involvement,

323 distant metastasis, and poor survival outcomes in prostate cancer. *J Clin Oncol* 31:1748-  
324 1757. 10.1200/JCO.2012.43.1882

325 Chen CH, Joshi AU, and Mochly-Rosen D. 2016. The Role of Mitochondrial Aldehyde  
326 Dehydrogenase 2 (ALDH2) in Neuropathology and Neurodegeneration. *Acta Neurol*  
327 *Taiwan* 25(4):111-123. 10196099/254111

328 Dai J, Van Wie PG, Fai LY, Kim D, Wang L, Poyil P, Luo J, and Zhang Z. 2016.  
329 Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of  
330 colorectal cancer cells. *Toxicol Appl Pharmacol* 311:106-112.  
331 10.1016/j.taap.2016.09.016

332 David JM, Dominguez C, Hamilton DH, and Palena C. 2016. The IL-8/IL-8R Axis: A Double  
333 Agent in Tumor Immune Resistance. *Vaccines (Basel)* 4. 10.3390/vaccines4030022

334 Deliu IC, Georgescu EF, and Bezna MC. 2014. Analysis of prognostic factors in colorectal  
335 carcinoma. *Rev Med Chir Soc Med Nat Iasi* 118:808-816.

336 Demirkol S, Gomceli I, Isbilen M, Dayanc BE, Tez M, Bostanci EB, Turhan N, Akoglu M,  
337 Ozyerli E, Durdu S, Konu O, Nissan A, Gonen M, and Gure AO. 2017. A Combined  
338 ULBP2 and SEMA5A Expression Signature as a Prognostic and Predictive Biomarker  
339 for Colon Cancer. *J Cancer* 8:1113-1122. 10.7150/jca.17872

340 Duband-Goulet I, Courvalin JC, and Buendia B. 1998. LBR, a chromatin and lamin binding  
341 protein from the inner nuclear membrane, is proteolyzed at late stages of apoptosis. *J Cell*  
342 *Sci* 111 ( Pt 10):1441-1451.

343 Fukumoto M, Kurisu S, Yamada T, and Takenawa T. 2015. alpha-Actinin-4 enhances colorectal  
344 cancer cell invasion by suppressing focal adhesion maturation. *PLoS One* 10:e0120616.  
345 10.1371/journal.pone.0120616

346 Goncalves V, Henriques AF, Pereira JF, Neves Costa A, Moyer MP, Moita LF, Gama-Carvalho  
 347 M, Matos P, and Jordan P. 2014. Phosphorylation of SRSF1 by SRPK1 regulates  
 348 alternative splicing of tumor-related Rac1b in colorectal cells. *RNA* 20:474-482.  
 349 10.1261/rna.041376.113

350 Heagerty PJ, Lumley T, and Pepe MS. 2000. Time-dependent ROC curves for censored survival  
 351 data and a diagnostic marker. *Biometrics* 56:337-344.

352 Hu Y, Chen HY, Yu CY, Xu J, Wang JL, Qian J, Zhang X, and Fang JY. 2014. A long non-  
 353 coding RNA signature to improve prognosis prediction of colorectal cancer. *Oncotarget*  
 354 5:2230-2242. 1895 10.18632/oncotarget.1895

355 Hur K, Toiyama Y, Schetter AJ, Okugawa Y, Harris CC, Boland CR, and Goel A. 2015.  
 356 Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. *J*  
 357 *Natl Cancer Inst* 107. 10.1093/jnci/dju492

358 Ji H, Greening DW, Barnes TW, Lim JW, Tauro BJ, Rai A, Xu R, Adda C, Mathivanan S, Zhao  
 359 W, Xue Y, Xu T, Zhu HJ, and Simpson RJ. 2013. Proteome profiling of exosomes  
 360 derived from human primary and metastatic colorectal cancer cells reveal differential  
 361 expression of key metastatic factors and signal transduction components. *Proteomics*  
 362 13:1672-1686. 10.1002/pmic.201200562

363 Knijn N, Tol J, and Punt CJ. 2010. Current issues in the targeted therapy of advanced colorectal  
 364 cancer. *Discov Med* 9:328-336.

365 Lambrechts D, Thienpont B, Thuillier V, Sagaert X, Moisse M, Peuteman G, Pericay C,  
 366 Folprecht G, Zalcberg J, Zilocchi C, Margherini E, Chiron M, and Van Cutsem E. 2015.  
 367 Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal  
 368 cancer treated with aflibercept in the first-line setting. *Br J Cancer* 113:1027-1034.

10.1038/bjc.2015.329

Lee CL, Huang CJ, Yang SH, Chang CC, Huang CC, Chien CC, and Yang RN. 2016. Discovery of genes from feces correlated with colorectal cancer progression. *Oncol Lett* 12:3378-3384. 10.3892/ol.2016.5069

Li H, Chen YX, Wen JG, and Zhou HH. 2017. Metastasis-associated in colon cancer 1: A promising biomarker for the metastasis and prognosis of colorectal cancer. *Oncol Lett* 14:3899-3908. 10.3892/ol.2017.6670

Li R, Zhao Z, Sun M, Luo J, and Xiao Y. 2016. ALDH2 gene polymorphism in different types of cancers and its clinical significance. *Life Sci* 147:59-66. 10.1016/j.lfs.2016.01.028

Liew AW, Law NF, and Yan H. 2011. Missing value imputation for gene expression data: computational techniques to recover missing data from available information. *Brief Bioinform* 12:498-513. 10.1093/bib/bbq080

Linhares MM, Affonso RJ, Jr., Viana Lde S, Silva SR, Denadai MV, de Toledo SR, and Matos D. 2015. Genetic and Immunohistochemical Expression of Integrins ITGAV, ITGA6, and ITGA3 As Prognostic Factor for Colorectal Cancer: Models for Global and Disease-Free Survival. *PLoS One* 10:e0144333. 10.1371/journal.pone.0144333

Marzouk O, and Schofield J. 2011. Review of histopathological and molecular prognostic features in colorectal cancer. *Cancers (Basel)* 3:2767-2810. 10.3390/cancers3022767

Nagata M, Noman AA, Suzuki K, Kurita H, Ohnishi M, Ohyama T, Kitamura N, Kobayashi T, Uematsu K, Takahashi K, Kodama N, Kawase T, Hoshina H, Ikeda N, Shingaki S, and Takagi R. 2013. ITGA3 and ITGB4 expression biomarkers estimate the risks of locoregional and hematogenous dissemination of oral squamous cell carcinoma. *BMC Cancer* 13:410. 10.1186/1471-2407-13-410

392 Paavilainen VO, Hellman M, Helfer E, Bovellan M, Annila A, Carlier MF, Permi P, and  
393 Lappalainen P. 2007. Structural basis and evolutionary origin of actin filament capping  
394 by twinfilin. *Proc Natl Acad Sci U S A* 104:3113-3118. 10.1073/pnas.0608725104

395 Provenzani A, Fronza R, Loreni F, Pascale A, Amadio M, and Quattrone A. 2006. Global  
396 alterations in mRNA polysomal recruitment in a cell model of colorectal cancer  
397 progression to metastasis. *Carcinogenesis* 27:1323-1333. 10.1093/carcin/bgi377

398 Qin S, Kim J, Arafat D, and Gibson G. 2012. Effect of normalization on statistical and biological  
399 interpretation of gene expression profiles. *Front Genet* 3:160. 10.3389/fgene.2012.00160

400 Roessler S, Lin G, Forgues M, Budhu A, Hoover S, Simpson RM, Wu X, He P, Qin LX, Tang  
401 ZY, Ye QH, and Wang XW. 2015. Integrative genomic and transcriptomic  
402 characterization of matched primary and metastatic liver and colorectal carcinoma. *Int J*  
403 *Biol Sci* 11:88-98. 10.7150/ijbs.10583

404 Rokavec M, Kaller M, Horst D, and Hermeking H. 2017. Pan-cancer EMT-signature identifies  
405 RBM47 down-regulation during colorectal cancer progression. *Sci Rep* 7:4687.  
406 10.1038/s41598-017-04234-2

407 Sameer AS. 2013. Colorectal cancer: molecular mutations and polymorphisms. *Front Oncol*  
408 3:114. 10.3389/fonc.2013.00114

409 Sanford JR, Wang X, Mort M, Vanduy N, Cooper DN, Mooney SD, Edenberg HJ, and Liu Y.  
410 2009. Splicing factor SFRS1 recognizes a functionally diverse landscape of RNA  
411 transcripts. *Genome Res* 19:381-394. 10.1101/gr.082503.108

412 Shagisultanova E, Gaponova AV, Gabbasov R, Nicolas E, and Golemis EA. 2015. Preclinical  
413 and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. *Gene*  
414 567:1-11. 10.1016/j.gene.2015.04.086

415 Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL,  
 416 Notterman DA, and Domany E. 2009. Association of survival and disease progression  
 417 with chromosomal instability: a genomic exploration of colorectal cancer. *Proc Natl*  
 418 *Acad Sci U S A* 106:7131-7136. 10.1073/pnas.0902232106

419 Shelmerdine SC, Semple T, Wallis C, Aurora P, Moledina S, Ashworth MT, and Owens CM.  
 420 2017. Filamin A (FLNA) mutation-A newcomer to the childhood interstitial lung disease  
 421 (ChILD) classification. *Pediatr Pulmonol* 52:1306-1315. 10.1002/ppul.23695

422 Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, and Jemal A. 2017a.  
 423 Colorectal cancer statistics, 2017. *CA Cancer J Clin* 67:177-193. 10.3322/caac.21395

424 Siegel RL, Miller KD, and Jemal A. 2017b. Cancer Statistics, 2017. *CA Cancer J Clin* 67:7-30.  
 425 10.3322/caac.21387

426 Stein U, and Schlag PM. 2007. Clinical, biological, and molecular aspects of metastasis in  
 427 colorectal cancer. *Recent Results Cancer Res* 176:61-80.

428 Tian ZQ, Shi JW, Wang XR, Li Z, and Wang GY. 2015. New cancer suppressor gene for  
 429 colorectal adenocarcinoma: filamin A. *World J Gastroenterol* 21:2199-2205.  
 430 10.3748/wjg.v21.i7.2199

431 Vellinga TT, Kranenburg O, Frenkel N, Ubink I, Marvin D, Govaert K, van Schelven S,  
 432 Hagendoorn J, and Borel Rinkes IH. 2017. Lymphangiogenic Gene Expression Is  
 433 Associated With Lymph Node Recurrence and Poor Prognosis After Partial Hepatectomy  
 434 for Colorectal Liver Metastasis. *Ann Surg*. 10.1097/SLA.0000000000002430

435 Xu G, Zhang M, Zhu H, and Xu J. 2017. A 15-gene signature for prediction of colon cancer  
 436 recurrence and prognosis based on SVM. *Gene* 604:33-40. 10.1016/j.gene.2016.12.016

437 Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, Coussens LM, Gast CE,



438       Geltzeiler CB, Hansen L, Kelley KA, Lopez CD, Rana SR, Ruhl R, Tsikitis VL, Vaccaro  
439       GM, Wong MH, and Mayo SC. 2017. Colorectal Cancer Liver Metastasis: Evolving  
440       Paradigms and Future Directions. *Cell Mol Gastroenterol Hepatol* 3:163-173.  
441       10.1016/j.jcmgh.2017.01.006  
442   Zhang S, and Xie C. 2017. The role of OXCT1 in the pathogenesis of cancer as a rate-limiting  
443       enzyme of ketone body metabolism. *Life Sci* 183:110-115. 10.1016/j.lfs.2017.07.003  
444  
445  
446

# [24412] Metastasis genes relate to colon cancer

ORIGINALITY REPORT

37%

SIMILARITY INDEX

## PRIMARY SOURCES

- 1

[www.spandidos-publications.com](http://www.spandidos-publications.com)  
Internet

122 words — 3%
- 2

Jiang-Hui Zeng, Liang Liang, Rong-Quan He, Rui-Xue Tang, Xiao-Yong Cai, Jun-Qiang Chen, Dian-Zhong Luo, Gang Chen. "Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma", *Oncotarget*, 2017  
Crossref

111 words — 3%
- 3

Meng Zhou, Yanying Sun, Yifan Sun, Wanying Xu, Zhaoyue Zhang, Hengqiang Zhao, Zhaohua Zhong, Jie Sun. "Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer", *Oncotarget*, 2016  
Crossref

93 words — 2%
- 4

Chaoyang Zhang, Li Peng, Yaqin Zhang, Zhaoyang Liu, Wenling Li, Shilian Chen, Guancheng Li. "The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data", *Medical Oncology*, 2017  
Crossref

69 words — 2%
- 5

[mdpi.com](http://mdpi.com)  
Internet

58 words — 1%
- 6

[www.biorxiv.org](http://www.biorxiv.org)  
Internet

48 words — 1%
- 7

[www.dovepress.com](http://www.dovepress.com)  
Internet

47 words — 1%

8	Susan C. Shelmerdine, Thomas Semple, Colin Wallis, Paul Aurora, Shahin Moledina, Michael T. Ashworth, Catherine M. Owens. " Filamin A ( ) mutation-A newcomer to the childhood interstitial lung disease (ChILD) classification ", <i>Pediatric Pulmonology</i> , 2017 Crossref	46 words — 1%
9	Song Zhang, Caifeng Xie. "The role of OXCT1 in the pathogenesis of cancer as a rate-limiting enzyme of ketone body metabolism", <i>Life Sciences</i> , 2017 Crossref	40 words — 1%
10	<a href="http://jcs.biologists.org">jcs.biologists.org</a> Internet	39 words — 1%
11	<a href="http://preview-wjso.biomedcentral.com">preview-wjso.biomedcentral.com</a> Internet	37 words — 1%
12	<a href="http://repositorio.insa.pt">repositorio.insa.pt</a> Internet	36 words — 1%
13	Bo Gao, Tian Yu, Dongbo Xue, Boshi Sun, Qin Shao, Hani Choudhry, Victoria Marcus, Jiannis Ragoussis, Yuguo Zhang, Weihui Zhang, Zu-hua Gao. "A multidimensional integration analysis reveals potential bridging targets in the process of colorectal cancer liver metastasis", <i>PLOS ONE</i> , 2017 Crossref	36 words — 1%
14	<a href="http://www.oncotarget.com">www.oncotarget.com</a> Internet	32 words — 1%
15	<a href="http://wjso.biomedcentral.com">wjso.biomedcentral.com</a> Internet	30 words — 1%
16	Jiang, Qian, You-Cheng Yu, Xiao-Jun Ding, Yin Luo, and Hong Ruan. "Bioinformatics Analysis Reveals Significant Genes and Pathways to Targetfor Oral Squamous Cell Carcinoma", <i>Asian Pacific Journal of Cancer Prevention</i> , 2014. Crossref	27 words — 1%

- 
- 17 [Fleshman, . "RNA expression of the molecular signature genes for metastasis in colorectal cancer", Oncology Reports, 2011.](#) 25 words — 1%  
Crossref
- 
- 18 [Sun, Baoyong, Fangxin Wang, Min Li, and Mingshan Yang. "Identifications of genetic differences between metastatic and non-metastatic osteosarcoma samples based on bioinformatics analysis", Medical Oncology, 2015.](#) 25 words — 1%  
Crossref
- 
- 19 [Thomas T. Vellinga, Onno Kranenburg, Nicola Frenkel, Inge Ubink et al. "Lymphangiogenic Gene Expression Is Associated With Lymph Node Recurrence and Poor Prognosis After Partial Hepatectomy for Colorectal Liver Metastasis", Annals of Surgery, 2017](#) 24 words — 1%  
Crossref
- 
- 20 [www.nature.com](#) 21 words — 1%  
Internet
- 
- 21 [dknet.org](#) 21 words — 1%  
Internet
- 
- 22 [Hao-Yuan Wang, Ji-Ye Li, Xiu Liu, Xiao-Yan Yan et al. "A three ion channel genes-based signature predicts prognosis of primary glioblastoma patients and reveals a chemotherapy sensitive subtype", Oncotarget, 2016](#) 19 words — < 1%  
Crossref
- 
- 23 [Bockhorn, Jessica, Rachel Dalton, Chika Nwachukwu, Simo Huang, Aleix Prat, Kathy Yee, Ya-Fang Chang, Dezheng Huo, Yujia Wen, Kaitlin E. Swanson, Tyler Qiu, Jun Lu, Seo Young Park, M. Eileen Dolan, Charles M. Perou, Olufunmilayo I. Olopade, Michael F. Clarke, Geoffrey L. Greene, and Huiping Liu. "MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11", Nature Communications, 2013.](#) 18 words — < 1%  
Crossref
- 
- 24 [Elena Shagisultanova, Anna V. Gaponova, Rashid Gabbasov, Emmanuelle Nicolas, Erica A. Golemis.](#) 18 words — < 1%

- 25 Huang, Xin-Ping, Jin Hou, Xiao-Yun Shen, Chao-Yuan Huang, Xue-Hui Zhang, Yu-An Xie, and Xiao-Ling Luo. "Microrna-486-5p, downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting p85 $\alpha$ ", FEBS Journal, 2014. 18 words — < 1%

Crossref

- 26 Mingwei Chen, Baoquan Liu, Jianbing Xiao, Yingnan Yang, Yafang Zhang. "A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma", Oncotarget, 2017 15 words — < 1%

Crossref

- 27 pdfs.semanticscholar.org 15 words — < 1%

Internet

- 28 Luai R. Zarour, Sudarshan Anand, Kevin G. Billingsley, William H. Bisson et al. "Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions", Cellular and Molecular Gastroenterology and Hepatology, 2017 14 words — < 1%

Crossref

- 29 Yanli Wang, Ke Lv, Mei Zhao, Fengji Liang et al. "Expression profiles and functional annotation analysis of mRNAs in suprachiasmatic nucleus of Clock mutant mice", Gene, 2018 14 words — < 1%

Crossref

- 30 Workenhe, S.T.. "Infectious salmon anaemia virus (ISAV) isolates induce distinct gene expression responses in the Atlantic salmon (*Salmo salar*) macrophage/dendritic-like cell line TO, assessed using genomic techniques", Molecular Immunology, 200909 14 words — < 1%

Crossref

- 31 www.infona.pl 13 words — < 1%

Internet

- 
- 32 "Encyclopedia of Signaling Molecules", Springer Nature, 2018  
Crossref 13 words — < 1%
- 
- 33 Guangru Xu, Minghui Zhang, Hongxing Zhu, Jinhua Xu. "A 15-gene signature for prediction of colon cancer recurrence and prognosis based on SVM", Gene, 2017  
Crossref 12 words — < 1%
- 
- 34 NA. "Supplement 2, Proceedings of the 14th World Conference on Lung Cancer, Book 2", Journal of Thoracic Oncology, 2011  
Crossref 12 words — < 1%
- 
- 35 www.wjgnet.com  
Internet 12 words — < 1%
- 
- 36 f1000.com  
Internet 12 words — < 1%
- 
- 37 www.jove.com  
Internet 11 words — < 1%
- 
- 38 Upender Manne, Trafina Jadhav, Balananda-Dhurjati Kumar Putcha, Temesgen Samuel, Shivani Soni, Chandrakumar Shanmugam, Esther A. Suswam. "Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective", Current Colorectal Cancer Reports, 2016  
Crossref 11 words — < 1%
- 
- 39 C Criscitiello, M A Bayar, G Curigliano, F W Symmans et al. "A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer", Annals of Oncology, 2017  
Crossref 11 words — < 1%
- 
- 40 Chenhua Sun, Qi Yuan, Dongdong Wu, Xiaohu Meng, Baolin Wang. "Identification of core genes and outcome in gastric cancer using bioinformatics analysis", 11 words — < 1%



- 41

spandidos-publications.com

Internet

11 words — < 1%
- 42

ub-ed.ub.uni-greifswald.de

Internet

10 words — < 1%
- 43

biblioteca.universia.net

Internet

10 words — < 1%
- 44

www.science.gov

Internet

10 words — < 1%
- 45

Sven H. Loosen, Frank Tacke, Marcel Binnebösel, Catherine Leyh et al. "Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases", Oncotarget, 2018

Crossref

10 words — < 1%
- 46

Xianglong Tian, Xiaoqiang Zhu, Tingting Yan, Chenyang Yu, Chaoqin Shen, Ye Hu, Jie Hong, Haoyan Chen, Jing-Yuan Fang. "Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer", Molecular Oncology, 2017

Crossref

10 words — < 1%
- 47

SÃ,rensen, Karina Dalsgaard. "Predicting the future of advanced prostate cancer", The Lancet Oncology, 2012.

Crossref

10 words — < 1%
- 48

open.uct.ac.za

Internet

9 words — < 1%
- 49

rnajournal.cshlp.org

Internet

9 words — < 1%
- 50

Lindsey E Montefiori, Debora R Sobreira, Noboru J Sakabe, Ivy Aneas et al. "A promoter interaction

9 words — < 1%

51 Nagata, Masaki, Arhab A Noman, Kenji Suzuki, Hiroshi Kurita, Makoto Ohnishi, Tokio Ohyama, Nobutaka Kitamura, Takanori Kobayashi, Kohya Uematsu, Katsu Takahashi, Naoki Kodama, Tomoyuki Kawase, Hideyuki Hoshina, Nobuyuki Ikeda, Susumu Shingaki, and Ritsuo Takagi. "ITGA3 and ITGB4 expression biomarkers estimate the risks of locoregional and hematogenous dissemination of oral squamous cell carcinoma", BMC Cancer, 2013.

Crossref

52 Hur, K., Y. Toiyama, A. J. Schetter, Y. Okugawa, C. C. Harris, C. R. Boland, and A. Goel. "Identification of a Metastasis-Specific MicroRNA Signature in Human Colorectal Cancer", JNCI Journal of the National Cancer Institute, 2015.

Crossref

53 [ar.iiarjournals.org](http://ar.iiarjournals.org)

Internet

54 [bmccancer.biomedcentral.com](http://bmccancer.biomedcentral.com)

Internet

55 Xin Zhou, Zebo Huang, Lei Xu, Mingxia Zhu, Lan Zhang, Huo Zhang, Xiaping Wang, Hai Li, Wei Zhu, Yongqian Shu, Ping Liu. "A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer", Oncotarget, 2016

Crossref

56 [www.ijcep.com](http://www.ijcep.com)

Internet

57 [repositorio.uam.es](http://repositorio.uam.es)

Internet

58 Rong Xu, Alin Rai, Maoshan Chen, Wittaya Suwakulsiri, David W. Greening, Richard J.

Simpson. "Extracellular vesicles in cancer — implications for future improvements in cancer care", Nature Reviews Clinical Oncology, 2018

Crossref

---

59 Jun Wang, Peng Gao, Jingxu Sun, Jinxin Shi, Zhonghua Wu, Xi Zhong, Yongxi Song, Zhenning Wang. "A six-gene prognostic predictor for patients with gastric cancer", Oncotarget, 2018 8 words — < 1%

Crossref

---

60 Shun Liu, Tian-Bo Yang, Yue-Li Nan, An-Hua Li, Dong-Xiang Pan, Yang Xu, Shu Li, Ting Li, Xiao-Yun Zeng, Xiao-Qiang Qiu. "Genetic variants of cell cycle pathway genes predict disease-free survival of hepatocellular carcinoma", Cancer Medicine, 2017 8 words — < 1%

Crossref

---

61 Okugawa, Yoshinaga, Yuji Toiyama, Yasuhiko Mohri, Koji Tanaka, Mikio Kawamura, Junichiro Hiro, Toshimitsu Araki, Yasuhiro Inoue, Chikao Miki, and Masato Kusunoki. "Elevated serum concentration of monocyte chemotactic protein 4 (MCP-4) as a novel non-invasive prognostic and predictive biomarker for detection of metastasis in colorectal cancer : Serum MCP-4 in Colorectal Cancer", Journal of Surgical Oncology, 2016. 8 words — < 1%

Crossref

---

62 onlinelibrary.wiley.com 8 words — < 1%

Internet

---

63 Han, Cheng-Bo Sun, Li Ma, Jie-Tao Li, Ya. "The influence of mtDNA deletion on lung cancer cells under the conditions of hypoxia and irradiation", Lung, Dec 2014 Issue 8 words — < 1%

Publications

---

64 Zhou, Meng, Maoni Guo, Dongfeng He, Xiaojun Wang, Yinqiu Cui, Haixiu Yang, Dapeng Hao, and Jie Sun. "A potential signature of eight long non-coding RNAs predicts survival in patients with non-small cell lung cancer", Journal of Translational Medicine, 2015. 7 words — < 1%

Crossref

- 
- 65 Dai, Jin, Peter G. Van Wie, Leonard Yenwong Fai, Donghern Kim, Lei Wang, Pratheeshkumar Poyil, Jia Luo, and Zhuo Zhang. "Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells", Toxicology and Applied Pharmacology, 2016. 6 words — < 1%  
Crossref
- 
- 66 Li, Rui, Zihan Zhao, Mingyang Sun, Jiachi Luo, and Yechen Xiao. "ALDH2 gene polymorphism in different types of cancers and its clinical significance", Life Sciences, 2016. 6 words — < 1%  
Crossref
- 
- 67 Recent Results in Cancer Research, 2016. 6 words — < 1%  
Crossref
- 
- 68 Bin Xiao, Lidan Chen, Yongli Ke, Jianfeng Hang et al. "Identification of methylation sites and signature genes with prognostic value for luminal breast cancer", BMC Cancer, 2018 6 words — < 1%  
Crossref
- 
- 69 Min, Weijie, Yanan Li, Yihui Zhang, Dongwei Dai, Yiqun Cao, Zhijian Yue, and Jianmin Liu. "Role of the anti-glioma drug AT13148 in the inhibition of Notch signaling pathway", Gene, 2015. 6 words — < 1%  
Crossref
- 
- 70 "Non-coding RNAs in Colorectal Cancer", Springer Nature, 2016 6 words — < 1%  
Crossref
- 
- 71 Huarong Chen, Xiaoqiang Sun, Weiting Ge, Yun Qian, Rui Bai, Shu Zheng. "A seven-gene signature predicts overall survival of patients with colorectal cancer", Oncotarget, 2016 6 words — < 1%  
Crossref
- 
- 72 "Abstract", Hepatology International, 06/2008 6 words — < 1%  
Crossref

---

EXCLUDE QUOTES      OFF  
EXCLUDE BIBLIOGRAPHY   ON

EXCLUDE MATCHES      OFF